Stem Cell Therapy Treatment for Myotonic Muscular Dystrophy by Dr Alok Sharma, Mumbai, India. Improvement seen in just 3 months after Stem Cell Therapy Treatment for Myotonic Muscular Dystrophy by Dr Alok Sharma, Mumbai, India. After Stem Cell Therapy 1. He can walk without support... By: NeuroGen Brain And Spine Institute … Continue reading →

Stem Cell Therapy Treatment for Becker Muscular Dystrophy by Dr Alok Sharma, Mumbai, India. Improvement seen after Stem Cell Therapy Treatment for Becker Muscular Dystrophy by Dr Alok Sharma, Mumbai, India. Stem Cell Therapy done at Dr Alok Sharma NeuroGen Brain and Spine Institute... By: NeuroGen Brain And Spine Institute … Continue reading →

Stem cell 2 By: Jennifer Etter … Continue reading →

Are there special considerations for selecting a PMF treatment strategy in a younger person? Are there special considerations for selecting a PMF treatment strategy in a younger person (eg, 20-40 years of age)? Jeffrey Bryan, Pharm. D. The University... By: MPNUniversity … Continue reading →

May 28, 2013 Survival rates have increased significantly among patients who received blood stem cell transplants from both related and unrelated donors, according to a study published in the Journal of Clinical Oncology today. The study authors attribute the increase to several factors, including advances in HLA tissue typing, better supportive care and earlier referral for transplantation. The study analyzed outcomes for more than 38,000 transplant patients with life-threatening blood cancers and other diseases over a 12-year period -- capturing approximately 70 to 90 percent of all related and unrelated blood stem cell transplants performed in the U.S. It was led by Theresa Hahn, Ph.D., of Roswell Park Cancer Institute (RPCI), in collaboration with the Center for International Blood and Marrow Transplant Research (CIBMTR), the research arm of the National Marrow Donor Program (NMDP) and Be The Match. "This study shows that we are making significant progress, on a national level, in survival after transplantation. Patients across the country have benefited from the collaborative efforts of the CIBMTR, the NMDP and clinical researchers at individual transplant centers," said Dr. Hahn, an Associate Member and Associate Professor of Oncology in RPCI's Department of Medicine and first author on the study. "Our … Continue reading →

Featured Article Main Category: Stroke Also Included In: Stem Cell Research;Clinical Trials / Drug Trials Article Date: 28 May 2013 - 3:00 PDT Current ratings for: Stroke Patients Show Signs Of Recovery Following Stem Cell Trial 4.67 (3 votes) 4 (1 votes) Updated interim results of the Pilot Investigation of Stem Cells in Stroke (PISCES) study, which is testing the safety and tolerability of injecting neural stem cells into the brains of ischemic stroke patients, were reported on Monday at the 22nd European Stroke Conference in London. The stem cell trial started in 2010, with one stroke patient, an elderly Scotsman who was injected with ReN001 cells developed by ReNeuron Group plc, at the trial center at Southern General Hospital in Glasgow, UK. By 2012, there were six patients on the small trial, and an early set of results presented at an international conference showed that five of the six patients were showing some improvement and there had been no adverse side effects. Clare Walton, Research Communications Officer at the UK's Stroke Association says they are very excited about the results of the trial, but "we are currently at the beginning of a very long road and significant further development … Continue reading →

Public release date: 28-May-2013 [ | E-mail | Share ] Contact: Masatoshi Suzuki msuzuki@vetmed.wisc.edu University of Wisconsin-Madison MADISON, Wis. Transplantation of human stem cells in an experiment conducted at the University of Wisconsin-Madison improved survival and muscle function in rats used to model ALS, a nerve disease that destroys nerve control of muscles, causing death by respiratory failure. ALS (amyotrophic lateral sclerosis) is sometimes called "Lou Gehrig's disease." According to the ALS Association, the condition strikes about 5,600 Americans each year. Only about half of patients are alive three years after diagnosis. In work recently completed at the UW School of Veterinary Medicine, Masatoshi Suzuki, an assistant professor of comparative biosciences, and his colleagues used adult stem cells from human bone marrow and genetically engineered the cells to produce compounds called growth factors that can support damaged nerve cells. The researchers then implanted the cells directly into the muscles of rats that were genetically modified to have symptoms and nerve damage resembling ALS. In people, the motor neurons that trigger contraction of leg muscles are up to three feet long. These nerve cells are often the first to suffer damage in ALS, but it's unclear where the deterioration begins. Many … Continue reading →